NCT01942083View on ClinicalTrials.gov

A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)

PHASE1TerminatedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 29, 2013

Primary Completion Date

June 1, 2016

Study Completion Date

July 11, 2016

Conditions
Advanced Hepatocellular Carcinoma
Interventions
DRUG

OPB-111077

Trial Locations (1)

Unknown

Seoul & Gyeonggi-Do

Sponsors
All Listed Sponsors
lead

Korea Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

NCT01942083 - A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma) | Biotech Hunter | Biotech Hunter